The topic you requested could not be found.
Related topics are listed below.

2402: Disease Classification

Transplant Essential Data (TED) Manuals » 2402: Disease Classification

The Disease Classification Form is required for all transplants, including subsequent transplants on the comprehensive report form track and cellular therapy infusions when the indication is malignant hematologic disorder, non-malignant disorder or solid tumor. All…

Waldenstrom’s Macroglobulinemia Response Criteria

Comprehensive Disease-Specific Manuals » 2019/2119: Waldenström’s Macroglobulinemia (WM) » Waldenstrom’s Macroglobulinemia Response Criteria

*Reporting Disease Status on the Pre-TED Disease Classification (2402) Form: Not all of the Waldenstrom’s Macroglobulinemia response criteria correspond to the option values on the current Pre-TED Disease Classification (2402) Form. Please see the italicized text…

Q1-2: Disease Specificity

Comprehensive Disease-Specific Manuals » 2016/2116: Plasma Cell Disorders (PCD) » 2116: PCD Post-Infusion » Q1-2: Disease Specificity

Question 1: Specify the multiple myeloma / plasma cell disorder (PCD) classification: Specify the indication for transplant. This question will be auto-populated from the Pre-TED Disease Classification and Characteristics (2402) Form. Question 2: Specify preceding /…

Appendix M: HCT Critical Data Fields

Appendices » Appendix M: HCT Critical Data Fields

The following list of data fields have been identified as being critical to accurate outcome analyses. These fields are audited for each recipient selected for audit. The table below is a summary of many of the critical data points grouped by data field type. Critical…

Appendix O: Cellular Therapy Critical Fields

Appendices » Appendix O: Cellular Therapy Critical Fields

The following list of data fields have been identified as being critical to accurate outcome analyses. These fields are audited for each recipient selected for audit. The table below is a summary of many of the critical data points grouped by data field type. Critical…

2134: XLP Post-HCT

Comprehensive Disease-Specific Manuals » 2034/2134: X-Linked Lymphoproliferative Sydrome (XLP) » 2134: XLP Post-HCT

This form must be completed for all recipients randomized to the Comprehensive Report Form (CRF) track whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as “disorders of the immune system” and question 628 as X-Linked…

Transplant Essential Data (TED) Manuals

Transplant Essential Data (TED) Manuals

The Transplant Essential Data (TED) Manual section contains information on the successful completion of TED forms. The Pre-TED Manual has several links to disease specific response criteria which can be found in the Comprehensive Disease Specific Manual…

2133: WAS Post-HCT

Comprehensive Disease-Specific Manuals » 2033/2133: Wiskott-Aldrich Syndome (WAS) » 2133: WAS Post-HCT

This form must be completed for all recipients randomized to the Comprehensive Report Form (CRF) track whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as Wiskott-Aldrich Syndrome under “disorders of the immune system.” The…

2139: HLH Post-HCT

Comprehensive Disease-Specific Manuals » 2039/2139: Hemophagocytic Lymphohistiocytosis (HLH) » 2139: HLH Post-HCT

The Hemophagocytic Lymphohistiocytosis Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures HLH-specific Post-HCT data such as the disease assessment since the date of the last report. This form must be completed for all recipients…

Q177: Clinical Features Just Prior to the Preparative Regimen

Comprehensive Disease-Specific Manuals » 2029/2129: Fanconi Anemia / Constitutional Anemia » 2029: Fanconi Anemia / Constitutional Anemia Pre-HCT » Q177: Clinical Features Just Prior to the Preparative Regimen

Question 177: What was the recipient’s disease status immediately prior to the preparative regimen? The pre-HCT disease status is determined by a disease assessment, such as hematologic testing, pathology study, and / or physician assessment. Indicate the…

2034: XLP Pre-HCT

Comprehensive Disease-Specific Manuals » 2034/2134: X-Linked Lymphoproliferative Sydrome (XLP) » 2034: XLP Pre-HCT

The X-Linked Lymphoproliferative Syndrome Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures XLP-specific pre-HCT data such as: the recipient’s clinical and genetic findings at the time of diagnosis and prior to the start of the…

2033: WAS Pre-HCT

Comprehensive Disease-Specific Manuals » 2033/2133: Wiskott-Aldrich Syndome (WAS) » 2033: WAS Pre-HCT

The Wiskott-Aldrich Syndrome Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures WAS-specific pre-HCT data such as: the recipient’s clinical and genetic findings at the time of diagnosis and prior to the start of the preparative regimen,…

2115: JMML Post HCT

Comprehensive Disease-Specific Manuals » 2015/2115: Juvenile Myelomonocytic Leukemia (JMML) » 2115: JMML Post HCT

This form must be completed for all recipients randomized to the Comprehensive Report Form (CRF) track whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as Myelodysplastic (MDS)/myeloproliferative (MPN) diseases and question 480…

2039: HLH Pre-HCT

Comprehensive Disease-Specific Manuals » 2039/2139: Hemophagocytic Lymphohistiocytosis (HLH) » 2039: HLH Pre-HCT

The Hemophagocytic Lymphohistiocytosis Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures HLH-specific Pre-HCT data such as the disease assessment, clinical and laboratory features at diagnosis, history of infection, pre-transplant therapy,…

2031: ID Pre-HCT

Comprehensive Disease-Specific Manuals » 2031/2131: Immune Deficiencies (ID) » 2031: ID Pre-HCT

The Immune Deficiency Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures ID-specific pre-HCT data such as: disease assessment at diagnosis, laboratory studies at diagnosis, clinical features assessed between diagnosis and the start of the…

2015: JMML Pre-HCT

Comprehensive Disease-Specific Manuals » 2015/2115: Juvenile Myelomonocytic Leukemia (JMML) » 2015: JMML Pre-HCT

The Juvenile Myelomonocytic Leukemia Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures JMML-specific pre-HCT data such as: the recipient’s hematologic and cytogenetic findings at the time of diagnosis and prior to the start of the…

2019: WM Pre-HCT

Comprehensive Disease-Specific Manuals » 2019/2119: Waldenström’s Macroglobulinemia (WM) » 2019: WM Pre-HCT

The Waldenström’s Macroglobulinemia/Lymphoplasmacytic Lymphoma Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures WM/LPL-specific pre-HCT data such as: the recipient’s clinical and genetic findings at the time of diagnosis and prior to…

2129: Fanconi Anemia / Constitutional Anemia Post-HCT

Comprehensive Disease-Specific Manuals » 2029/2129: Fanconi Anemia / Constitutional Anemia » 2129: Fanconi Anemia / Constitutional Anemia Post-HCT

This form must be completed for all recipients randomized to the Comprehensive Report Form (CRF) track and whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as Inherited Bone Marrow Failure Syndromes with a sub classification of…

2543: Mylotarg™ Supplemental Data Collection

Infection & Miscellaneous Manuals » 2543: Mylotarg™ Supplemental Data Collection

The Mylotarg™ Supplemental Data Collection Form (Form 2543) is designed to support a retrospective and prospective, multicenter, observational registry of patients with Acute Myeloid Leukemia (AML) treated with Mylotarg™ alone or in combination in regimen prior to…

2131: ID Post-HCT

Comprehensive Disease-Specific Manuals » 2031/2131: Immune Deficiencies (ID) » 2131: ID Post-HCT

The Immune Deficiency Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures ID-specific post-HCT data such as: laboratory studies post-HCT, clinical features assessed post-HCT, Post-HCT treatment, and status of hematologic engraftment. This…

2029: Fanconi Anemia / Constitutional Anemia Pre-HCT

Comprehensive Disease-Specific Manuals » 2029/2129: Fanconi Anemia / Constitutional Anemia » 2029: Fanconi Anemia / Constitutional Anemia Pre-HCT

The Fanconi Anemia / Constitutional Anemia Pre-HCT Form is one of the Comprehensive Report Forms. This form captures Fanconi Anemia-specific pre-infusion data such as: disease assessment at diagnosis, laboratory studies at diagnosis, pre-infusion therapy, most recent…

2119: WM Post-HCT

Comprehensive Disease-Specific Manuals » 2019/2119: Waldenström’s Macroglobulinemia (WM) » 2119: WM Post-HCT

This form must be completed for all recipients randomized to the Comprehensive Report Form (CRF) track whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as Non-Hodgkin lymphoma and the subtype is reported as Waldenström’s…

2113: CLL Post-Infusion

Comprehensive Disease-Specific Manuals » 2013/2113: Chronic Lymphocytic Leukemia (CLL) » 2113: CLL Post-Infusion

The Chronic Lymphocytic Leukemia Post-Infusion Data Form is one of the Comprehensive Report Forms. This form captures CLL-specific post-infusion data such as: disease assessment at the time of best response to HCT or cellular therapy, laboratory studies at the time of…

2013: CLL Pre-Infusion

Comprehensive Disease-Specific Manuals » 2013/2113: Chronic Lymphocytic Leukemia (CLL) » 2013: CLL Pre-Infusion

The Chronic Lymphocytic Leukemia Pre-Infusion Data Form is one of the Comprehensive Report Forms. This form captures CLL-specific pre-infusion data such as: disease assessment at diagnosis, laboratory studies at diagnosis, pre-infusion treatment for CLL, most recent…

2542: Mogamulizumab Supplemental Data Collection

Infection & Miscellaneous Manuals » 2542: Mogamulizumab Supplemental Data Collection

The Mogamulizumab Supplemental Data Collection Form (Form 2542) is designed to support a retrospective and prospective, multicenter, observational registry of patients treated with mogamulizumab alone or in combination, within one year prior to allogeneic hematopoietic…

4000: Cellular Therapy Essential Data Pre-Infusion

Cellular Therapy Manuals » 4000: Cellular Therapy Essential Data Pre-Infusion

This form must be completed for all recipients of cellular therapy (non-HCT) with or without a prior HCT. Recipients of CAR T cells, donor lymphocyte infusions, tumor-infiltrating lymphocytes, cytotoxic T cells are common cellular therapies that should be reported…

2128: Aplastic Anemia Post-HCT

Comprehensive Disease-Specific Manuals » 2028/2128: Aplastic Anemia » 2128: Aplastic Anemia Post-HCT

The Aplastic Anemia Post-HSCT Data Form is one of the Comprehensive Report Forms. This form captures aplastic anemia-specific post-HSCT disease assessment data for the reporting period. This form must be completed for all recipients whose primary disease, as reported…

2028: Aplastic Anemia Pre-Infusion

Comprehensive Disease-Specific Manuals » 2028/2128: Aplastic Anemia » 2028: Aplastic Anemia Pre-Infusion

This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Aplastic Anemia Pre-Infusion Data Form (Form 2028 – Revision 3). *Email comments regarding the content of the CIBMTR Forms Instruction Manual to:…

2030: SCD Pre-Infusion

Comprehensive Disease-Specific Manuals » 2030/2130: Sickle Cell Disease (SCD) » 2030: SCD Pre-Infusion

SCD Pre-Infusion Data The Sickle Cell Disease (SCD) Pre-Infusion Data Form (Form 2030) is one of the Comprehensive Report Forms. This form captures SCD-specific pre-infusion data such as: disease classification at diagnosis, transfusion status prior to the start of…

2018 Manual Updates

Getting Started » Getting Started » 2018 Manual Updates

December 2018 November 2018 October 2018 September 2018 August 2018 July 2018 June 2018 May 2018 April 2018 March 2018 February 2018 January 2018 Updates made during the current calendar year are included below. For updates prior to 2018, click on the subtopic…

2012: CML Pre-Infusion Data

Comprehensive Disease-Specific Manuals » 2012/2112: Chronic Myeloid Leukemia (CML) » 2012: CML Pre-Infusion Data

Chronic myelogenous leukemia (CML) is a slow-progressing cancer of the myeloid white blood cells. It is characterized by the increased proliferation of immature white blood cells (granulocytes) with damaged DNA, or blasts, which accumulate in the blood and bone marrow.…

2114: Myelodysplastic Syndrome (MDS) Post-Infusion

Comprehensive Disease-Specific Manuals » 2014/2114: Myelodysplastic Syndrome (MDS) » 2114: Myelodysplastic Syndrome (MDS) Post-Infusion

This form must be completed for all recipients who are randomized to the Comprehensive Report Form (CRF) track and whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as “Myelodysplastic Syndrome (MDS) (50)” The Myelodysplastic…

2130: SCD Post-Infusion

Comprehensive Disease-Specific Manuals » 2030/2130: Sickle Cell Disease (SCD) » 2130: SCD Post-Infusion

The Sickle Cell Disease Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures Sickle Cell Disease (SCD) post-HCT data for the reporting period. This form must be completed for all recipients whose primary disease, as reported on the Pre-TED…

2057: Myeloproliferative Neoplasm (MPN) Pre-Infusion

Comprehensive Disease-Specific Manuals » 2057/2157 Myeloproliferative Neoplasms (MPN) » 2057: Myeloproliferative Neoplasm (MPN) Pre-Infusion

The Myeloproliferative Neoplasms Pre-HCT Data Form is one of the Comprehensive Report Forms. This form captures MPN-specific pre-HCT data such as: disease assessment at diagnosis, laboratory studies at diagnosis, pre-HCT therapy, disease transformation, most recent…

2020 Manual Updates

Getting Started » Getting Started » 2020 Manual Updates

January 2020 February 2020 March 2020 April 2020 May 2020 June 2020 July 2020 August 2020 October 2020 December 2020 Updates made during the current calendar year are included below. For updates prior to 2020, click on the subtopic corresponding to the year of…

2018: LYM Pre-Infusion

Comprehensive Disease-Specific Manuals » 2018/2118: Hodgkin and Non-Hodgkin Lymphoma » 2018: LYM Pre-Infusion

Complete this form for recipients whose primary disease, reported on the Disease Classification Form (Form 2402), is Hodgkin Lymphoma (HL) or non-Hodgkin Lymphoma (NHL). One exception is Waldenstrom’s macroglobulinemia / lymphoplasmacytic lymphoma, for which, a…

Q58-77: Indication for Cellular Therapy

Cellular Therapy Manuals » 4000: Cellular Therapy Essential Data Pre-Infusion » Q58-77: Indication for Cellular Therapy

Question 58: What was the primary indication for performing treatment with cellular therapy? From the list provided, select the primary indication for which the recipient is receiving the cellular therapy. If the indication is in the list below and the cell therapy…

2126: Neuroblastoma Post-Infusion

Comprehensive Disease-Specific Manuals » 2026/2126: Neuroblastoma » 2126: Neuroblastoma Post-Infusion

The Neuroblastoma Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures neuroblastoma (NEU) post-HCT data for the reporting period. This form must be completed for all recipients whose primary disease, as reported on the Pre-TED Disease…

2116: PCD Post-Infusion

Comprehensive Disease-Specific Manuals » 2016/2116: Plasma Cell Disorders (PCD) » 2116: PCD Post-Infusion

The Plasma Cell Disorder Post-HCT Data Form is one of the Comprehensive Report Forms. This form captures plasma cell disorder (PCD) post-HCT data such as: disease assessment at the time of best response, hematologic and organ parameters at the time of best response,…

Q2-33: Disease Assessment

Comprehensive Disease-Specific Manuals » 2028/2128: Aplastic Anemia » 2028: Aplastic Anemia Pre-Infusion » Q2-33: Disease Assessment

Question 2: Was a bone marrow examination performed? (at diagnosis) Indicate Yes or No if a bone marrow examination was performed at diagnosis or prior to the first treatment of aplastic anemia. If a bone marrow examination was not performed or it is not known if one…

2014: Myelodyplastic Syndrome (MDS) Pre-Infusion

Comprehensive Disease-Specific Manuals » 2014/2114: Myelodysplastic Syndrome (MDS) » 2014: Myelodyplastic Syndrome (MDS) Pre-Infusion

The Myelodysplastic Pre-Infusion Data Form is one of the Comprehensive Report Forms. This form captures MDS-specific pre-infusion data such as: disease assessment at diagnosis, laboratory studies at diagnosis, pre-infusion therapy, disease transformation, most recent…

2112: CML Post-Infusion Data

Comprehensive Disease-Specific Manuals » 2012/2112: Chronic Myeloid Leukemia (CML) » 2112: CML Post-Infusion Data

Chronic myelogenous leukemia (CML) is a slow-progressing cancer of the myeloid white blood cells. It is characterized by the increased proliferation of immature white blood cells (granulocytes) with damaged DNA, or blasts, which accumulate in the blood and bone marrow.…

Q4-22: Organ Function Prior to the Preparative Regimen (Conditioning)

Comprehensive Baseline & Follow-up Manuals » 2000: Recipient Baseline » Q4-22: Organ Function Prior to the Preparative Regimen (Conditioning)

*Infusion Without a Preparative Regimen Complete questions 4-22 based on the most recent testing prior to infusion if no preparative regimen was given. Questions 4-22: Provide last laboratory values recorded for recipient’s organ function (testing done within 30…

2026: Neuroblastoma Pre-Infusion

Comprehensive Disease-Specific Manuals » 2026/2126: Neuroblastoma » 2026: Neuroblastoma Pre-Infusion

The Neuroblastoma Pre-HCT Data Form (Form 2026) is one of the Comprehensive Report Forms. This form captures neuroblastoma specific pre-HCT data such as: the recipient’s clinical and laboratory findings at the time of diagnosis and prior to the start of the…

Getting Started

Getting Started

Welcome to the CIBMTR Forms Instruction Manual. The Table of Contents on the left side of the screen is for navigational purposes; if you are on a mobile device you may find the Table on Contents on the top of the page. General Instructions provides useful general…

2017 Manual Updates

Getting Started » Getting Started » 2017 Manual Updates

December 2017 November 2017 October 2017 September 2017 August 2017 July 2017 June 2017 May 2017 April 2017 March 2017 February 2017 January 2017 !Hyperlinks Please note, hyperlinks on this page will not work for any manual sections which have been retired and / or…

2016: PCD Pre-Infusion

Comprehensive Disease-Specific Manuals » 2016/2116: Plasma Cell Disorders (PCD) » 2016: PCD Pre-Infusion

The Plasma Cell Disorder Pre-Infusion Data Form (Form 2016) is one of the Comprehensive Report Forms. This form captures PCD-specific pre-infusion data such as: disease classification at diagnosis, hematologic findings at the time of diagnosis and prior to the start of…

2400: Pre-TED

Transplant Essential Data (TED) Manuals » 2400: Pre-TED

*The Pre-TED Form is now required for all transplants, including subsequent transplants on the comprehensive report form track. All transplant centers participating in the CIBMTR must submit a Pre-TED Form for each allogeneic (related or unrelated) hematopoietic cell…

Q103-107: Post-HCT Therapy

Transplant Essential Data (TED) Manuals » 2450: Post-TED » Q103-107: Post-HCT Therapy

!Malignant Diseases Only Only complete questions 103-107 if the HCT being reported was given to treat a malignant disease. If the HCT being reported was given to treat a non-malignant disease, leave questions 103-107 blank. FormsNet3SM should enable / disable this…

Q96-163: Acute Lymphoblastic Leukemia

Transplant Essential Data (TED) Manuals » 2402: Disease Classification » Q96-163: Acute Lymphoblastic Leukemia

!Acute Lymphoblastic Lymphoma Due to the aggressive nature of precursor T- and precursor B-cell lymphoblastic lymphoma (or lymphoma / leukemia), the primary disease reported for recipients with these malignancies should be acute lymphoblastic leukemia (T-cell…

2118: LYM Post-Infusion

Comprehensive Disease-Specific Manuals » 2018/2118: Hodgkin and Non-Hodgkin Lymphoma » 2118: LYM Post-Infusion

Complete this form for recipients whose primary disease, reported on the Disease Classification Form (Form 2402), is Hodgkin Lymphoma (HL) or non-Hodgkin Lymphoma (NHL). One exception is Waldenstrom’s macroglobulinemia / lymphoplasmacytic lymphoma, for which, a…

2111: ALL Post-Infusion

Comprehensive Disease-Specific Manuals » 2011/2111: Acute Lymphoblastic Leukemia (ALL) » 2111: ALL Post-Infusion

The Acute Lymphoblastic Leukemia Post-Infusion Data Form (Form 2111) is one of the Comprehensive Report Forms. This form captures ALL-specific post-infusion data such as: the recipient’s best response to HCT or cellular therapy, cytogenetic and molecular findings at…

Q1-13: Disease Assessment at Diagnosis

Comprehensive Disease-Specific Manuals » 2010/2110: Acute Myelogenous Leukemia (AML) » 2010: AML Pre-Infusion » Q1-13: Disease Assessment at Diagnosis

Question 1: Is the disease (AML) therapy related? (not MDS / MPN) Agents such as radiation or systemic therapy used to treat other diseases (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma, and breast cancer) can damage the marrow and lead to a secondary malignancy such…

2110: AML Post-Infusion

Comprehensive Disease-Specific Manuals » 2010/2110: Acute Myelogenous Leukemia (AML) » 2110: AML Post-Infusion

The Acute Myelogenous Leukemia Post-Infusion Data Form (Form 2110) is one of the Comprehensive Report Forms. This form captures AML-specific post-infusion data such as: the recipient’s best response to HCT or cellular therapy, cytogenetic and molecular findings at…

Q103-113: Comorbid Conditions

Cellular Therapy Manuals » 4000: Cellular Therapy Essential Data Pre-Infusion » Q103-113: Comorbid Conditions

*Diagnosis of COVD-19 after the start of the lymphodepleting therapy: Questions 103 – 105 are intended to capture COVID-19 (SARS-CoV-2) infections diagnosed prior to the start of the lymphodepleting therapy / infusion. If a COVID-19 infection is diagnosed after the…

2011: ALL Pre-Infusion

Comprehensive Disease-Specific Manuals » 2011/2111: Acute Lymphoblastic Leukemia (ALL) » 2011: ALL Pre-Infusion

The Acute Lymphoblastic Leukemia Pre-Infusion Data Form (Form 2011) is one of the Comprehensive Report Forms. This form captures ALL-specific pre-infusion data such as: the recipient’s hematologic findings at the time of diagnosis and prior to the start of the…

Q3-95: Acute Myelogenous Leukemia

Transplant Essential Data (TED) Manuals » 2402: Disease Classification » Q3-95: Acute Myelogenous Leukemia

Acute Myelogenous Leukemia (AML) is a cancer of the white blood cells. It is characterized by the rapid proliferation of abnormal, immature myelocytes, known as myeloblasts, in the bone marrow. This accumulation of blasts in the marrow prevents the formation of healthy…

2157: Myeloproliferative Neoplasm (MPN) Post-Infusion

Comprehensive Disease-Specific Manuals » 2057/2157 Myeloproliferative Neoplasms (MPN) » 2157: Myeloproliferative Neoplasm (MPN) Post-Infusion

This form must be completed for all recipients who are randomized to the Comprehensive Report Form (CRF) track and whose primary disease is reported on the Pre-TED Disease Classification Form (Form 2402) as “Myeloproliferative Neoplasm (MPN) (1460)”. The…

Q1-2: Disease Assessment at Diagnosis

Comprehensive Disease-Specific Manuals » 2016/2116: Plasma Cell Disorders (PCD) » 2016: PCD Pre-Infusion » Q1-2: Disease Assessment at Diagnosis

Question 1: Specify the multiple myeloma / plasma cell disorder (PCD) classification: Specify the indication for transplant. This question will be auto-populated from the Pre-TED Disease Classification and Characteristics (2402) Form. See below for characteristics of…

2010: AML Pre-Infusion

Comprehensive Disease-Specific Manuals » 2010/2110: Acute Myelogenous Leukemia (AML) » 2010: AML Pre-Infusion

The Acute Myelogenous Leukemia Pre-Infusion Data Form (Form 2010) is one of the Comprehensive Report Forms. This form captures AML-specific pre-infusion data such as: the recipient’s hematologic findings at the time of diagnosis and prior to the start of the…

Appendix H: MDS/MPN Subtypes

Appendices » Appendix H: MDS/MPN Subtypes

The following MDS / MPN subtypes are used on the Pre-TED Disease Classification (2402) Form, AML Pre-Infusion (2010), the MDS Pre-Infusion (2014) Form, and the MPN Pre-Infusion (2057) Form.1 Myelodysplastic Syndrome (MDS) Subtypes Myelodysplastic Syndrome with…

Q11-40: Diagnostic Studies (Measured Prior to First Disease Treatment)

Comprehensive Disease-Specific Manuals » 2057/2157 Myeloproliferative Neoplasms (MPN) » 2057: Myeloproliferative Neoplasm (MPN) Pre-Infusion » Q11-40: Diagnostic Studies (Measured Prior to First Disease Treatment)

Report findings prior to any first treatment of the primary disease for which the HCT / cellular therapy is being performed. If the recipient’s MPN transformed, report the studies from the original diagnosis. If multiple studies were performed prior to the start of…

Q87-115: Comorbid Conditions

Transplant Essential Data (TED) Manuals » 2400: Pre-TED » Q87-115: Comorbid Conditions

*Diagnosis of COVID-19 after the start of the preparative regimen: Questions 87 – 89 are intended to capture COVID-19 (SARS-CoV-2) infections diagnosed prior to the start of the preparative regimen / infusion. If a COVID-19 infection is diagnosed after the start of…

Q119-122: Current Disease Status

Transplant Essential Data (TED) Manuals » 2450: Post-TED » Q119-122: Current Disease Status

!Malignant Diseases Only Only complete questions 119-122 if the HCT being reported was given to treat a malignant disease. If the HCT being reported was given to treat a non-malignant disease, leave questions 117-120 blank. FormsNet3SM should enable / disable this…

2019 Manual Updates

Getting Started » Getting Started » 2019 Manual Updates

January 2019 February 2019 March 2019 April 2019 May 2019 June 2019 July 2019 August 2019 October 2019 December 2019 Updates made during the current calendar year are included below. For updates prior to 2019, click on the subtopic corresponding to the year of…

Q33-57: Product Identification

Cellular Therapy Manuals » 4000: Cellular Therapy Essential Data Pre-Infusion » Q33-57: Product Identification

Question 33: Are any of the products associated with this course of cell therapy genetically modified? Genetically modified products include any product that was manipulated to alter its gene expression through the insertion of different genes or editing of genes. An…

2450: Post-TED

Transplant Essential Data (TED) Manuals » 2450: Post-TED

Transplant centers participating in the CIBMTR must submit a Post-TED Form for recipients who meet any of the following criteria: Recipient receives a transplant at a United States center designated as a TED-only center. Recipient receives a transplant at a United…

Q108-118: Relapse or Progression Post-HCT

Transplant Essential Data (TED) Manuals » 2450: Post-TED » Q108-118: Relapse or Progression Post-HCT

!Malignant Diseases Only Only complete questions 108-118 if the HCT being reported was given to treat a malignant disease. If the HCT being reported was given to treat a non-malignant disease, leave questions 108-118 blank. Questions 111-118 must be completed…

Q80-102: Disease Assessment at the Time of Best Response to HCT

Transplant Essential Data (TED) Manuals » 2450: Post-TED » Q80-102: Disease Assessment at the Time of Best Response to HCT

!Malignant Diseases Only Only complete questions 80-102 if the HCT being reported was given to treat a malignant disease. If the HCT being reported was given to treat a non-malignant disease, leave questions 80-102 blank. FormsNet3SM should enable / disable this…